Year All20262025202420232022202120202019 November 14, 2022 Beckley Psytech successfully completes Phase I clinical study of lead candidate BPL-003, a novel benzoate formulation of 5-MeO-DMT November 10, 2022 atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update November 1, 2022 atai Life Sciences to Participate in November Investor Events & Healthcare Conferences November 1, 2022 atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update October 25, 2022 atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression October 20, 2022 atai Life Sciences Announces R&D Day Agenda October 18, 2022 atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology October 12, 2022 atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD October 5, 2022 atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT October 4, 2022 atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
November 14, 2022 Beckley Psytech successfully completes Phase I clinical study of lead candidate BPL-003, a novel benzoate formulation of 5-MeO-DMT
November 10, 2022 atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
November 1, 2022 atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
November 1, 2022 atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
October 25, 2022 atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
October 18, 2022 atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
October 12, 2022 atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
October 5, 2022 atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
